Stewart Trust Cancer Fellows
Johns Hopkins University-Kimmel Comprehensive Cancer Center
Dr. Fan Pan, Ph.D. from the Chinese Institute of Preventive Medicine – Assistant Professor in the Department of Oncology at Johns Hopkins University.
Research: Dr. Pan’s work focuses on further exploring the role of the HIF-1 in regulating the Th17/Treg balance in vivo and examining the efficacy of combinatorial therapy applying HIF-1 Inhibitors in conjunction with Treg depletion in mouse tumor cells. Fpan1@jhmi.edu
Yale School of Medicine
Dr. Tae Hoon Kim, Ph.D. from Harvard University – Assistant Professor of Genetics at Yale University School of Medicine.
Research : Dr. Kim’s work focuses on analyzing transcriptional regulatory events in the genome in order to discover, reconstruct and analyze novel regulatory mechanisms and networks encoded in the genome, with particular focus on changes occurring during carcinogenesis. Recently, Dr. Kim and his team have determined the locations of a large number of insulators in the genome of primary fibroblast cells. http://www.taehoonkim.org/
Dr. Qin Yan, Ph.D. from the University of Oklahoma – Assistant Professor of Pathology at Yale University School of Medicine.
Research: Dr. Yan’s work focuses on epigenetic regulation by histone demethylases in cancer and stem cells. In particular, he studies the roles and regulatory mechanisms of histone demethylases for trimethylated lysine-4 in histone H3, the epigenetic mark for transcriptionally active chromatin. Qin.email@example.com
Columbia University Medical Center
Dr. Katia Basso, Ph.D the University of Padova, Italy. Assistant Professor of Clinical Pathology and Cell Biology in the Institute for Cancer Genetics at Columbia University. Dr. Basso’s work aims to functionally characterize MEF2B, a transcription factor that has been recently identified as a master regulator of the germinal center (GC) reaction and whose genomic locus is targeted by activating mutations in non-Hodgkin B cell lymphomas (B-NHL). Kb451@columbia.edi
Raul Rabadan, PhD, Autonoma University, Madrid, Spain . Assistant Professor
Department of Biomedical Informatics, Center for Computational Biology and Bioinformatics.
Research: Dr. Rabadan’s research focuses on developing tools to analyze genomic data, extracting the relevant information to understand the molecular biology, population genetics, and evolution. firstname.lastname@example.org
Harvard Medical School
Dr. Steven McCarroll, Ph.D University of California, San Francisco – Assistant Professor, Department of Genetics. Research: developing integrative molecular and statistical approaches, then using these new ways of seeing to make basic insights about human disease. He conceived and led the development of hybrid SNP/CNV arrays that combine molecular SNP assays with dedicated copy-number probes (McCarroll et al., Nat Genet 2008), a research technology that is now used across human genetics and cancer genetics to analyze genomes for deletions, duplicaitons and SNPs simultaneously. email@example.com
Dr. Joseph Loparo, Ph.D MIT – Assitant Professor of Biomedical Chemistry and Molecular Pahramcology.
Research: His work focuses on developing and applying single-molecule methods to better understand the molecular mechanisms involved in genome maintenace. He is currently studying DNA damage tolerance, chromosome organization and homologous recombination. Joseph.firstname.lastname@example.org
Dr. Mary Gehring, Ph.D in Plant Biology at the University of California Berkeley- Assistant Professor of Biology at MIT. Research: Dr. Gehring’s work explores the relationship between two key components of the epigenome, the polycomb group (PcG) complex and DNA methylation. She will focus on whether DNA demethylation promotes PRC2 binfing and identify suppressors of mutations in the EZH2 homolog MEA. email@example.com
Dr. Piyush Gupta, Ph.D in Biology from MIT – Assistant Professor of Biology at MIT. Research: Dr. Gupta’s lab studies the molecular mechanisms that regulate cell-state behavior in normal tissues and in cancer. In particular, it is focused on understanding the mechanisms that contribute to the progression of breast cancer, as well as understanding the biology of normal and cancerous breast stem cells. firstname.lastname@example.org
Yale Cancer Center
Jun Lu, Ph.D Boston University – Assistant Professor Department of Genetics.
Research: Dr. Lu’s work explores a potential new paradigm of targeted cancer therapy by restoring the activity of haploinsufficient tumor suppressor Tet2. Unlike conventional tumor suppressors, a haploinsufficient tumor suppressor is often mutated on a single allele in patients, thus providing the theoretical possibility of restoring or over-driving its activity from the remaining wild-type copy. Jun.email@example.com
Columbia University Medical Center
Kenneth Olive, Ph.D MIT — Assistant Professor, Department of Medicine, Division of Digestive and Liver Disease.
Research: Dr. Olive’s research focuses on Preclinical evaluation of Bmi1 inhibitor in Pancreatic Ductal Adenocarcinoma. A series of pharmacological experiments using a genetically engineered mouse model of pancreatic cancer to investigate the potential efficacy of a novel small molecule inhibitor of the Bmi1 protein.
Duke University Medical Center
Oren Becher, MD Johns Hopkins School of Medicine - Assistant Professor, Department of Pediatrics Division of Pediatric Hematology-Oncology.
Research: Dr. Becher’s areas of research interests are Diffuse Intrinsic Pontine Gliomas- Genomics, Diffuse Intrinsic Pontine Gliomas- Mouse modeling, Diffuse Intrinsic Pontine Gliomas- PI3K pathway blockade, Diffuse Intrinsic Pontine Gliomas- Blood Brain Barrier/Drug Delivery Medulloblastomas.
Kris Wood, Ph.D MIT - Assistant Professor, Department of Pharmacology and Cancer Biology, School of Medicine.
Research: Dr. Wood’s lab is developing advanced functional genomic technologies that allow it to systematically map the genetic determinants of drug sensitivity and then directly connect these to effective therapeutic strategies and analytical approaches to design selective combination therapeutics as well as methods for the direct screening of therapeutic targets in patient-derived tumors. firstname.lastname@example.org
Harvard Medical School
Michaela Gack, Ph.D FAU Erlangen-Nuremberg, Germany – Assistant Professor (Microbiology)
Research: Dr. Gack’s work looks at molecular details of how innate immune sensors detect viral infections and then induce signaling cascades that trigger type-I interferon (IFN) mediated innate immune responses.
Johns Hopkins Kimmel Cancer Center
Sandra B. Gabelli, Ph.D Johns Hopkins University – Assistant Professor Department of Medicine
Research: Dr. Gabelli’s research is the design of inhibitors of PI3K that will lead to effective and novel anti-cancer therapies. She will target the newly elucidated PIP2 site and on the other she will target the protein-protein interactions that result from the oncogenic E545K mutant. email@example.com
Sridhar Nimmagadda, Ph.D Wayne State University – Assistant Professor Department of Radiology, Clinical Pharmacology, Oncology.
Research: The long term goal of Dr. Nimmagadda’s lab is to develop and evaluate highly specific positron emission tomography (PET), single photon emission computed tomography (SPECT) and Optical imaging probes for all the chemokine receptors and use these agents to elucidate chemokine receptor role in the tumor microenvironment/inflammation/infection in real time. The work is focused on the development of molecular imaging probes for metastatic disease marker CXCR4. Snimmag1@jhmi.edu
David Pincus, Ph.D University of California, San Francisco.
Research: Dr. Pincus’s research focuses on targeting post translational regulation of Hsf1 to unmask intrinsic proteomic instability in cancer cells.
Yale Cancer Center
Don Nguyen, Ph.D University of Rochester – Assistant Professor Pathology.
Research: Dr Nguyen’s goal is to Identify novel non-coding genomic elements that link epithelial lineage specification in the airways to cancer metastasis. A novel long intergenic RNA as an epigenetic modulator of lung cancer metastasis. Don.firstname.lastname@example.org